Peptide Nucleic Acid Probes for Pretargeted Affibody-Mediated Delivery of Cytotoxic Payloads to HER2-Positive Carcinoma
Bioconjugate Chemistry · 19.08.2026 · 37 (8) · 1562-1570
DOI: 10.1021/acs.bioconjchem.6c00035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 30.07.2026. Verfasst von Jacob Clinton und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm106…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Peptide Nucleic Acids, Drug Delivery Systems. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancerfonden, Svenska S?llskapet f?r Medicinsk Forskning, Knut och Alice Wallenbergs Stiftelse.
Abstract (Originalsprache)
This study investigates how the structural design of secondary PNA probes affects their ability to carry the cytotoxic agent DM1 in a novel affibody-PNA-based pretargeting approach directed at Human Epidermal growth factor Receptor 2 (HER2)-expressing cells. Six different DM1-conjugated secondary 8-mer PNA probes with strategic hydrophilic modifications were designed and evaluated. Surface plasmon resonance analysis confirmed that the modifications preserved hybridization to the HER2-targeting affibody-PNA primary probe, with all secondary probes showing similar binding kinetics (KD = 310–660 pM). Biodistribution studies in nontumor-bearing NMRI mice with lutetium-177 (177Lu)-labeled secondary probes revealed that probe modifications dramatically influenced organ distribution patterns. The secondary probes SP2, SP5, and SPc demonstrated favorable biodistribution profiles with reduced accumulation in critical organs, i.e., liver and kidneys. Receptor-mediated endocytosis was also affected by secondary probe design, showing an increase in cellular internalization for SP5 (20.4% after 24 h) compared to SP2 (12.1%). Our findings highlight how rational design can optimize in vivo pharmacokinetics while preserving binding properties essential for effective pretargeting, providing a foundation for developing novel targeted cytotoxic delivery systems with potentially improved therapeutic indexes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm10691, Sweden.
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala75185, Sweden.
ORCID-Profile: Eleftherios Papalanis, Anzhelika Vorobyeva, Torbjörn Gräslund, Amelie Eriksson Karlström, Maryam Oroujeni
Förderung
- Cancerfonden
- Svenska S?llskapet f?r Medicinsk Forskning
- Knut och Alice Wallenbergs Stiftelse
- Swedish Research Council (VR)
Zitieren
APA
Clinton, J., Westerlund, K., Haraldsson, A., Nordén, E., Hagelin, T., Papalanis, E., Ud-Din, M., Vorobyeva, A., Gräslund, T., Eriksson Karlström, A., & Oroujeni, M. (2026). Peptide Nucleic Acid Probes for Pretargeted Affibody-Mediated Delivery of Cytotoxic Payloads to HER2-Positive Carcinoma. Bioconjugate Chemistry, 37(8), 1562-1570. https://doi.org/10.1021/acs.bioconjchem.6c00035
Vancouver
Clinton J, Westerlund K, Haraldsson A, Nordén E, Hagelin T, Papalanis E, et al. Peptide Nucleic Acid Probes for Pretargeted Affibody-Mediated Delivery of Cytotoxic Payloads to HER2-Positive Carcinoma. Bioconjugate Chemistry. 2026;37(8):1562-1570. doi:10.1021/acs.bioconjchem.6c00035
BibTeX
@article{Clinton2026,
author = {Clinton, Jacob and Westerlund, Kristina and Haraldsson, Astrid and Nordén, Ebba and Hagelin, Tilde and Papalanis, Eleftherios and Ud-Din, Moeen and Vorobyeva, Anzhelika and Gräslund, Torbjörn and Eriksson Karlström, Amelie and Oroujeni, Maryam},
title = {Peptide Nucleic Acid Probes for Pretargeted Affibody-Mediated Delivery of Cytotoxic Payloads to HER2-Positive Carcinoma},
journal = {Bioconjugate Chemistry},
year = {2026},
volume = {37},
number = {8},
pages = {1562--1570},
doi = {10.1021/acs.bioconjchem.6c00035}
}
EUVIMED